251 related articles for article (PubMed ID: 28300852)
21. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
[TBL] [Abstract][Full Text] [Related]
22. Tracking actinic keratosis of face and scalp treated with 0.015% ingenol mebutate to identify clinical and dermoscopic predictors of treatment response.
Pampena R; Benati E; Borsari S; Bombonato C; Lombardi M; Raucci M; Mirra M; Lallas A; Apalla Z; Papadimitriou I; Moscarella E; Kyrgidis A; Argenziano G; Pellacani G; Longo C
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1461-1468. PubMed ID: 29356164
[TBL] [Abstract][Full Text] [Related]
23. Field Treatment of Actinic Keratosis With Ingenol Mebutate.
Berman B; Stockfleth E
J Drugs Dermatol; 2016 May; 15(5):535-42. PubMed ID: 27168262
[TBL] [Abstract][Full Text] [Related]
24. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
Keating GM
Drugs; 2012 Dec; 72(18):2397-405. PubMed ID: 23231025
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial.
Samorano LP; Torezan LA; Sanches JA
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1822-7. PubMed ID: 25727104
[TBL] [Abstract][Full Text] [Related]
26. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes.
Augustin M; Tu JH; Knudsen KM; Erntoft S; Larsson T; Hanke CW
J Am Acad Dermatol; 2015 May; 72(5):816-21. PubMed ID: 25770879
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
28. Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives.
Gameiro L; Tovo LFR; Sanches Júnior JA; Aprahamian I
An Bras Dermatol; 2019 Jul; 94(3):313-319. PubMed ID: 31365660
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest.
Hanke CW; Berman B; Swanson N; Pariser DM; Weiss JS; Bukhalo M; Skov T; Villumsen J; Siegel D
J Drugs Dermatol; 2017 May; 16(5):438-444. PubMed ID: 28628679
[TBL] [Abstract][Full Text] [Related]
30. Local skin reactions following the administration of topical ingenol mebutate for actinic keratosis.
Conde-Taboada A; Mercado B; Aranegui B; González-Guerra E; López-Bran E
Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469731
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses.
Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK
JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119
[TBL] [Abstract][Full Text] [Related]
32. A dose-finding trial with a novel ingenol derivative (ingenol disoxate: LEO 43204) for field treatment of actinic keratosis on full face or 250 cm
Bourcier M; Stein Gold L; Guenther L; Andreassen CM; Selmer J; Goldenberg G
J Dermatolog Treat; 2017 Nov; 28(7):652-658. PubMed ID: 28264612
[TBL] [Abstract][Full Text] [Related]
33. Granuloma faciale successfully treated with ingenol mebutate.
Bobyr I; Campanati A; Consales V; Giangiacomi M; Diotallevi F; Offidani A
Dermatol Ther; 2016 Sep; 29(5):325-329. PubMed ID: 27364361
[TBL] [Abstract][Full Text] [Related]
34. Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: a pilot study.
Jubert-Esteve E; Del Pozo-Hernando LJ; Izquierdo-Herce N; Bauzá-Alonso A; Martín-Santiago A; Jones-Caballero M
Actas Dermosifiliogr; 2015 Oct; 106(8):644-50. PubMed ID: 26130156
[TBL] [Abstract][Full Text] [Related]
35. Relationship between severity of the local skin reactions and the rate of local skin reaction resolution in patients treated with ingenol mebutate gel.
Jim On SC; Knudsen KM; Skov T; Lebwohl M
Clin Cosmet Investig Dermatol; 2016; 9():211-6. PubMed ID: 27601928
[TBL] [Abstract][Full Text] [Related]
36. Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques.
Ruini C; Hartmann D; Bastian M; Ruzicka T; French LE; Berking C; von Braunmühl T
J Biophotonics; 2019 Jul; 12(7):e201800391. PubMed ID: 30653833
[TBL] [Abstract][Full Text] [Related]
37. Clinical Response to Ingenol Mebutate in Patients With Actinic Keratoses.
Batalla A; Flórez Á; Feal C; Peón G; Abalde MT; Salgado-Boquete L; de la Torre C
Actas Dermosifiliogr; 2015 Dec; 106(10):e55-61. PubMed ID: 26055975
[TBL] [Abstract][Full Text] [Related]
38. Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: A single arm retrospective study.
Ricci F; Tambone S; Neri L; Fania L; Piccioni A; Guerriero C; Fargnoli MC; Peris K
J Dermatolog Treat; 2016 Nov; 27(6):525-530. PubMed ID: 27043050
[TBL] [Abstract][Full Text] [Related]
39. Survey of Patient Satisfaction With Ingenol Mebutate Gel Treatment for Actinic Keratosis From a Community Dermatology Practice.
Schaefer D
Skinmed; 2016; 14(4):259-265. PubMed ID: 27784514
[TBL] [Abstract][Full Text] [Related]
40. Histological examination confirms clinical clearance of actinic keratoses following treatment with ingenol mebutate 0·05% gel.
Ulrich M; Reinhold U; Skov T; Elvang Søndergaard R; Guitera P
Br J Dermatol; 2017 Jan; 176(1):71-80. PubMed ID: 27518593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
